Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C25H34O7 |
Molecular Weight | 446.5333 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@]3(O)C[C@H](CC[C@]3(C=O)[C@@]1([H])CC[C@]4(C)[C@H](CC[C@]24O)C5=CC(=O)OC5)OC(C)=O
InChI
InChIKey=JLZAERUVCODZQO-VWCUIIQSSA-N
InChI=1S/C25H34O7/c1-15(27)32-17-3-8-23(14-26)19-4-7-22(2)18(16-11-21(28)31-13-16)6-10-25(22,30)20(19)5-9-24(23,29)12-17/h11,14,17-20,29-30H,3-10,12-13H2,1-2H3/t17-,18+,19-,20+,22+,23-,24-,25-/m0/s1
semisynthetic C3 acetyl ester of the aglycone strophanthidin. Acetylstrophanthidin inhibits sodium-potassium adenosinetriphosphatase (Na -K ATPase) and causes an inotropic effect. The effect of acetylstrophanthidin is first seen within half a minute to five minutes and becomes maximal in about ten minutes. This rapid action obviates the effect of time, which is so important for subsidence of precipitationg causes of cardiac failure. Severe pulmonic, coronary, and aortic valvular disease, as well as old age, tended to predispose the patients to unusual acetylstrophanthidin sensitivity. Acetylstrophanthidin may cause nausea and vomiting.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Sodium/potassium-transporting ATPase (Oryctolagus cuniculus) Sources: https://www.ncbi.nlm.nih.gov/pubmed/239798 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Doses
Dose | Population | Adverse events |
---|---|---|
2.7 mg 4 times / hour multiple, intravenous (total daily dose) Highest studied dose Dose: 2.7 mg, 4 times / hour Route: intravenous Route: multiple Dose: 2.7 mg, 4 times / hour Sources: |
unhealthy, ADULT n = 30 Health Status: unhealthy Condition: heart disease Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 30 Sources: |
Other AEs: ventricular bigemin... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
ventricular bigemin | 1 pt | 2.7 mg 4 times / hour multiple, intravenous (total daily dose) Highest studied dose Dose: 2.7 mg, 4 times / hour Route: intravenous Route: multiple Dose: 2.7 mg, 4 times / hour Sources: |
unhealthy, ADULT n = 30 Health Status: unhealthy Condition: heart disease Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 30 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Biphasic effect of cardiac glycosides on action potential duration in isolated Purkinje fibers. | 2001 Sep |
|
Regulation of vocal fold transepithelial water fluxes. | 2001 Sep |
|
Denervation of vagal cardiopulmonary receptors by injection of kainic acid into the nodose ganglia in dogs. | 2002 Nov 29 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13309667
The initial dose varied from 0.15 to 0.6 mg. Subsequent doses, if given, varied from 0.1 to 0.6 mg at intervals of one to fifteen minutes.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16825310
Acetylstrophanthidin (ACS, 4 uM) alters Ca(2+) transients in completely Na(+)-free conditions in intact ferret and cat ventricular myocytes. In intact ferret myocytes (stimulated at 0.2 Hz), ACS enhanced Ca(2+) transients and cell shortening during twitches. Acute inotropic effects of ACS depend on the presence of Na(+) and a functional Na(+)-Ca(2+) exchanger in ferret and cat myocytes (rather than alternate Na(+)-independent mechanisms).
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
59028
Created by
admin on Sat Dec 16 10:42:56 GMT 2023 , Edited by admin on Sat Dec 16 10:42:56 GMT 2023
|
PRIMARY | |||
|
92954
Created by
admin on Sat Dec 16 10:42:56 GMT 2023 , Edited by admin on Sat Dec 16 10:42:56 GMT 2023
|
PRIMARY | |||
|
200-474-0
Created by
admin on Sat Dec 16 10:42:56 GMT 2023 , Edited by admin on Sat Dec 16 10:42:56 GMT 2023
|
PRIMARY | |||
|
JG33H36364
Created by
admin on Sat Dec 16 10:42:56 GMT 2023 , Edited by admin on Sat Dec 16 10:42:56 GMT 2023
|
PRIMARY | |||
|
DTXSID40101893
Created by
admin on Sat Dec 16 10:42:56 GMT 2023 , Edited by admin on Sat Dec 16 10:42:56 GMT 2023
|
PRIMARY | |||
|
261075
Created by
admin on Sat Dec 16 10:42:56 GMT 2023 , Edited by admin on Sat Dec 16 10:42:56 GMT 2023
|
PRIMARY | |||
|
60-38-8
Created by
admin on Sat Dec 16 10:42:56 GMT 2023 , Edited by admin on Sat Dec 16 10:42:56 GMT 2023
|
PRIMARY |
ACTIVE MOIETY